CN112823003A - α-2-肾上腺素受体激动剂用于改善视力的用途 - Google Patents

α-2-肾上腺素受体激动剂用于改善视力的用途 Download PDF

Info

Publication number
CN112823003A
CN112823003A CN201980065608.3A CN201980065608A CN112823003A CN 112823003 A CN112823003 A CN 112823003A CN 201980065608 A CN201980065608 A CN 201980065608A CN 112823003 A CN112823003 A CN 112823003A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
improvement
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980065608.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·蒂巴斯
D·W·吉尔
W·陈
M·阿尔坎塔拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN112823003A publication Critical patent/CN112823003A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980065608.3A 2018-08-21 2019-08-20 α-2-肾上腺素受体激动剂用于改善视力的用途 Pending CN112823003A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21
US62/720,671 2018-08-21
PCT/US2019/047305 WO2020041340A1 (en) 2018-08-21 2019-08-20 The use of alpha-2-adrenergic receptor agonists for improving vision

Publications (1)

Publication Number Publication Date
CN112823003A true CN112823003A (zh) 2021-05-18

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980065608.3A Pending CN112823003A (zh) 2018-08-21 2019-08-20 α-2-肾上腺素受体激动剂用于改善视力的用途

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514732A (ja) * 2020-02-20 2023-04-07 アラーガン、インコーポレイテッド アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CN1950067A (zh) * 2004-04-30 2007-04-18 阿勒根公司 改善视力的α－2肾上腺素能受体激动剂眼内植入物和方法
CN104717981A (zh) * 2012-07-19 2015-06-17 路易斯·费莉佩·贝哈拉诺雷斯特雷波 眼用制剂及用于改善老花眼的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
WO2012149381A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016515583A (ja) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CN1950067A (zh) * 2004-04-30 2007-04-18 阿勒根公司 改善视力的α－2肾上腺素能受体激动剂眼内植入物和方法
CN104717981A (zh) * 2012-07-19 2015-06-17 路易斯·费莉佩·贝哈拉诺雷斯特雷波 眼用制剂及用于改善老花眼的方法

Also Published As

Publication number Publication date
WO2020041340A1 (en) 2020-02-27
JP2021534217A (ja) 2021-12-09
BR112021003295A2 (pt) 2021-05-18
AU2019325486A1 (en) 2021-03-25
KR20210047323A (ko) 2021-04-29
CO2021003460A2 (es) 2021-04-08
AR115991A1 (es) 2021-03-17
EP3840750A1 (en) 2021-06-30
MX2021002112A (es) 2021-07-16
US20220288031A1 (en) 2022-09-15
SG11202101730SA (en) 2021-03-30
PH12021550372A1 (en) 2021-11-29
IL280990A (en) 2021-04-29
US20240358682A1 (en) 2024-10-31
US20210205273A1 (en) 2021-07-08
CA3110318A1 (en) 2020-02-27
CL2021000440A1 (es) 2021-09-20
TW202021584A (zh) 2020-06-16
US20220160623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
Wang et al. Depth-of-focus of the human eye: theory and clinical implications
Mester et al. Functional outcomes after implantation of Tecnis ZM900 and Array SA40 multifocal intraocular lenses
Fukuyama et al. Relationship between apparent accommodation and corneal multifocality in pseudophakic eyes
US20240358682A1 (en) Use of alpha-2-adrenergic receptor agonists for improving vision
KR102472774B1 (ko) 안과용 약학 조성물 및 이와 관련된 용도
US20240390330A1 (en) Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes
US11077053B2 (en) Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20240335425A1 (en) Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision
Hayashi et al. All-distance visual acuity and contrast visual acuity in eyes with a refractive multifocal intraocular lens with minimal added power
Dias-Santos et al. The impact of multifocal intraocular lens in retinal imaging with optical coherence tomography
HK40053072A (en) The use of alpha-2-adrenergic receptor agonists for improving vision
Sayegh et al. The Boston keratoprosthesis provides a wide depth of focus
Ishii et al. Mesopic contrast sensitivity and ocular higher-order aberrations in eyes with conventional spherical intraocular lenses
Soleimani et al. Visual outcomes following implantation of intracorneal rings with sharp and round triangular cross-section designs in keratoconus
Salgado et al. Pupil versus 1 st Purkinje capsulotomy centration with femtosecond laser: long term outcomes with a sinusoidal trifocal lens
Mazzoni Clinical and biochemical evaluation of two Extended-Depth of Focus (EDOF) intraocular lenses: a prospective randomized trial
Leyland Do Multifocal Intraocular Lenses Improve Visual Function Following Cataract Surgery?

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053072

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210518

WD01 Invention patent application deemed withdrawn after publication